Systemic Lupus Erythematosus trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Systemic Lupus Erythematosus. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month8 studies across 5 companies, in the next 180 days.
September 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusNCT05039840Percentage of participants who achieved a Systemic Lupus Erythematosus Responder Index (SRI-4) response at Week 24. | Phase 2 | Active, not recruiting | 2026-09-03 | in 14 d | 2026-08-06 |
| BIIB | Biogen | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04961567Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52 | Phase 3 | Active, not recruiting | 2026-09-27 | in 38 d | 2026-01-29 |
| BIIB | Biogen | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04895241Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52 | Phase 3 | Active, not recruiting | 2026-09-30 | in 41 d | 2026-02-10 |
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)NCT05617677Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] response | Phase 3 | Active, not recruiting | 2026-10-19 | in 60 d | 2025-12-03 |
| BMY | Bristol-Myers Squibb | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusNCT05620407Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] response | Phase 3 | Active, not recruiting | 2026-10-19 | in 60 d | 2025-12-02 |
December 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132NCT06875960Number of participants treated with BMS-986165 | Phase 4 | Recruiting | 2026-12-01 | in 103 d | 2026-03-30 |
| RNAC | Cartesian Therapeutics | Descartes-08 for Patients With Systemic Lupus ErythematosusNCT06038474Assess safety and tolerability of Descartes-08 in patients with systemic lupus erythematosus (SLE) | Phase 2 | Active, not recruiting | 2026-12-01 | in 103 d | 2026-03-27 |
| CGEM | Cullinan Therapeutics Inc. | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusNCT06613360Safety and tolerability | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-06-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Systemic Lupus Erythematosus
most recently updated first130 studies match. Showing the first 100 of 130 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Anifrolumab Pregnancy StudyNCT07049653observationalRisk of major congenital malformations (MCM) | — | Recruiting | — | Systemic Lupus Erythematosus | 500 | 2026-06-04 | 2030-12-10 | in 1,573 d | 2026-08-19 |
| CABA | Cabaletta Bio | $493M | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusNCT06121297To evaluate incidence of adverse events | Phase 1/2 | Recruiting | Biological: CABA-201, CABA-201 | Systemic Lupus Erythematosus, Lupus Nephritis | 28 | 2024-02-16 | Dec 2029 | ≤ 1,229 d | 2026-08-18 |
| AZN | AstraZeneca | — | Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersNCT06594068Area under the milk concentration-time curve during a dosing interval | Phase 4 | Recruiting | Drug: Anifrolumab | Systemic Lupus Erythematosus | 16 | 2026-01-16 | 2027-08-31 | in 376 d | 2026-08-18 |
| FATE | Fate Therapeutics | $307M | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisNCT07570862Complete Renal Response (CRR) at Week 26 | Phase 2 | Recruiting | Biological: FT819 | Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | 53 | 2026-07-27 | 2029-07-01 | in 1,046 d | 2026-08-17 |
| AZN | AstraZeneca | — | An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsNCT05835310Part A- Anifrolumab serum concentration | Phase 3 | Recruiting | Biological: Anifrolumab · Drug: Placebo | Systemic Lupus Erythematosus | 100 | 2024-03-14 | 2028-10-05 | in 777 d | 2026-08-14 |
| BIIB | Biogen | $31.4B | An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT05352919Number of Participants with Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Enrolling by invitation | Drug: Litifilimab, Litifilimab-matching placebo | Systemic Lupus Erythematosus (SLE) | 864 | 2022-06-10 | 2030-03-29 | in 1,317 d | 2026-08-13 |
| AZN | AstraZeneca | — | Anifrolumab Malignancy and Serious Infections StudyNCT07000110observationalMalignancies | — | Recruiting | Drug: Anifrolumab | Systemic Lupus Erythematosus | 3,506 | 2026-01-26 | 2031-11-30 | in 1,928 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLENCT06897930PHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE) | Phase 1/2 | Recruiting | Biological: AZD0120 · Drug: Cyclophosphamide, Fludarabine | Lupus Erythematosus, Systemic | 150 | 2025-04-21 | 2029-05-01 | in 985 d | 2026-08-12 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.NCT05879718results2026-08-11Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12 | Phase 2 | Terminatedsponsor's stated reason: Pfizer has made an internal business decision to not continue this study. This decision was not due to safety concerns or clinical effect reasons or requests from any regulatory authorities. | Drug: Placebo, PF-06823859 | Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous | 8 | 2023-07-07 | 2025-06-05actual | — | 2026-08-11 |
| AZN | AstraZeneca | — | The Anifrolumab PRIM ProgramNCT06795893observationalMajor congenital malfunctions | — | Recruiting | Drug: Anifrolumab | Systemic Lupus Erythematosus | 240 | 2025-11-07 | 2031-04-15 | in 1,699 d | 2026-08-11 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)NCT06977724Number of Participants with Adverse Events (AEs) | Phase 1 | Recruiting | Drug: ABBV-319 | Dry Eye Syndrome, Systemic Lupus Erythematosus | 36 | 2025-08-26 | Mar 2029 | ≤ 954 d | 2026-08-10 |
| AMGN | Amgen | $229.9B | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesNCT06570798Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE) | Phase 2 | Recruiting | Drug: Inebilizumab, Blinatumomab | Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis | 220 | 2025-07-16 | 2028-08-06 | in 717 d | 2026-08-07 |
| CRSP | CRISPR Therapeutics | $5.1B | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseaseNCT06925542To evaluate the safety of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM | Phase 1 | Recruiting | Biological: CTX112 | SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis | 80 | 2025-03-10 | 2031-12-31 | in 1,959 d | 2026-08-07 |
| AZN | AstraZeneca | — | A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus ErythematosusNCT07751848The proportion of patients who achieve DORIS remission at week 52 | Phase 3 | Not yet recruiting | Drug: Anifrolumab | Lupus Erythematosus, Systemic | 417 | 2026-09-04 | 2028-08-25 | in 736 d | 2026-08-07 |
| SNY | Sanofi | — | Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusNCT05039840Percentage of participants who achieved a Systemic Lupus Erythematosus Responder Index (SRI-4) response at Week 24. | Phase 2 | Active, not recruiting | Drug: SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC | Systemic Lupus Erythematosus | 109 | 2021-11-10 | 2026-09-03 | in 14 d | 2026-08-06 |
| AZN | AstraZeneca | — | Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsNCT07201558Safety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) | Phase 1 | Recruiting | Biological: Surovatamig | Rheumatoid Arthritis, Systemic Lupus Erythematosus | 48 | 2025-12-02 | 2028-06-27 | in 677 d | 2026-07-29 |
| AZN | AstraZeneca | — | Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusNCT04877691British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response | Phase 3 | Active, not recruiting | Drug: Medi-546, Placebo | Systemic Lupus Erythematosus | 367 | 2021-06-08 | 2025-08-22actual | — | 2026-07-27 |
| AZN | AstraZeneca | — | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.NCT06916806Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events. | Phase 1 | Recruiting | Drug: AZD5492 | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis | 72 | 2025-05-01 | 2027-05-05 | in 258 d | 2026-07-23 |
| AZN | AstraZeneca | — | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusNCT07430306Attainment of DORIS remission | Phase 3 | Recruiting | Drug: Anifrolumab | Systemic Lupus Erythematosus | 245 | 2026-04-13 | 2029-01-26 | in 890 d | 2026-07-23 |
| AZN | AstraZeneca | — | Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.NCT07330245observationalNumber and percentage of patients achieving LLDAS5 | — | Recruiting | Biological: Anifrolumab | Lupus Erythematosus, Systemic | 218 | 2025-12-31 | 2028-09-30 | in 772 d | 2026-07-22 |
| ALMS | Alumis Inc | $2.1B | Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusNCT05966480To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placebo | Phase 2 | Active, not recruiting | Drug: Envudeucitinib, Placebo | SLE | 408 | 2023-06-26 | 2026-06-23actual | — | 2026-07-21 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsNCT07175285observationalNumber of of participants achieving Definition of Remission in Systemic Lupus Erythematosus (DORIS) at 6 months along with the 95% CI. | — | Recruiting | Drug: Current standard of care treatment options | Systemic Lupus Erythematosus (SLE) | 223 | 2025-10-08 | 2028-03-24 | in 582 d | 2026-07-21 |
| AZN | AstraZeneca | — | INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World UseNCT06314282observationalPGA | — | Recruiting | — | Systemic Lupus Erythematosus (SLE) | 200 | 2024-10-22 | 2027-12-31 | in 498 d | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07276958Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Drug: LY4298445, LY4298445 | Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis | 63 | 2026-02-04 | Mar 2028 | ≤ 589 d | 2026-07-17 |
| AZN | AstraZeneca | — | Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in RussiaNCT06759519observationaldisease activity status at the time of patient visit to the doctor measured with SLEDAI-2K, expressed as the mean SLEDAI-2K total score at Visit 2. | — | Completed | — | Systemic Lupus Erythematosus | 637 | 2024-08-30 | 2025-09-19actual | — | 2026-07-09 |
| AZN | AstraZeneca | — | Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)NCT07688980Anifrolumab serum concentrations through Week 4 | Phase 1 | Not yet recruiting | Combination product: Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS | Systemic Lupus Erythematosus | 92 | 2026-10-30 | 2029-04-13 | in 967 d | 2026-07-07 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study of E6742 in Participants With Systemic Lupus ErythematosusNCT07515014Percentage of Participants who Achieve a BICLA Response with Low Dose of OCS (Prednisone or Equivalent) at Week 24 | Phase 2 | Recruiting | Drug: E6742 · Other: Placebo | Systemic Lupus Erythematosus | 256 | 2026-03-31 | 2028-08-05 | in 716 d | 2026-07-02 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07607964Change from Baseline in B Cells in Blood | Phase 1 | Recruiting | Drug: ABBV-519, ABBV-519 | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 30 | 2026-05-28 | Jan 2029 | ≤ 895 d | 2026-07-01 |
| AZN | AstraZeneca | — | Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersNCT06659029observationalComposite outcome of all major congenital malformations (MCMs) | — | Recruiting | Drug: Anifrolumab | Systemic Lupus Erythematosus | 442 | 2025-07-01 | 2031-04-15 | in 1,699 d | 2026-06-24 |
| AZN | AstraZeneca | — | NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine CareNCT07424261observationalProportion and number of patients who fulfill criteria for definition of remission in SLE (DORIS remission) | — | Recruiting | — | Lupus Erythematosus, Systemic | 125 | 2026-03-19 | 2029-08-31 | in 1,107 d | 2026-06-24 |
| AZN | AstraZeneca | — | SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)NCT05141201observationalIncidence of ADRs | — | Active, not recruiting | — | Lupus Erythematosus, Systemic | 1,620 | 2021-12-21 | 2027-03-31 | in 223 d | 2026-06-17 |
| AZN | AstraZeneca | — | Anifrolumab Real-world Treatment Outcomes in Systemic Lupus ErythematosusNCT06673043observationalChange from index date in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score | — | Active, not recruiting | Drug: Anifrolumab | Lupus Erythematosus, Systemic | 105 | 2025-02-28 | 2028-06-30 | in 680 d | 2026-06-16 |
| CGEM | Cullinan Therapeutics Inc. | $1.3B | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusNCT06613360Safety and tolerability | Phase 1 | Recruiting | Drug: CLN-978 | SLE, SLE (Systemic Lupus) | 24 | 2025-01-21 | Dec 2026 | ≤ 133 d | 2026-06-05 |
| AZN | AstraZeneca | — | A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus ErythematosusNCT07630714Maximum observed serum (peak) concentration (Cmax) | Phase 2 | Not yet recruiting | Combination product: Anifrolumab + APFS | Systemic Lupus Erythematosus | 24 | 2026-07-28 | 2030-09-03 | in 1,475 d | 2026-06-05 |
| AZN | AstraZeneca | — | AZAHAR Study To Describe Anifrolumab in a Real-World SettingNCT06626945observationalSystemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score | — | Completed | — | Systemic Lupus Erythematosus (SLE) | 152 | 2025-02-03 | 2025-06-05actual | — | 2026-06-04 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of DS-7011a in Patients With Systemic Lupus ErythematosusNCT05638802results2026-05-28Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus | Phase 1/2 | Completed | Drug: DS-7011a, Placebo | Systemic Lupus Erythematosus | 26 | 2023-06-07 | 2025-04-01actual | — | 2026-05-28 |
| AZN | AstraZeneca | — | A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical PracticeNCT05637112observationalDisease activity assessed by the Physician Global Assessment (PGA) | — | Active, not recruiting | Other: None (Observational study) | Systemic Lupus Erythematosus | 551 | 2023-02-27 | 2030-12-30 | in 1,593 d | 2026-05-26 |
| FATE | Fate Therapeutics | $307M | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseNCT06308978Number of participants with treatment-emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: FT819, Fludarabine, Cyclophosphamide, Bendamustine | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis | 244 | 2024-03-28 | 2027-09-30 | in 406 d | 2026-05-22 |
| SNY | Sanofi | — | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic DiseasesNCT06647069Incidence of treatment-emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: SAR448501 | Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) | 62 | 2025-03-27 | 2029-06-25 | in 1,040 d | 2026-05-22 |
| AZN | AstraZeneca | — | Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)NCT04931563results2026-05-20Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo | Phase 3 | Completed | Biological: Anifrolumab · Drug: placebo | Active Systemic Lupus Erythematosus | 277 | 2021-09-13 | 2025-04-07actual | — | 2026-05-20 |
| ABBV | AbbVie | $457.5B | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusNCT05843643Percentage of Participants Achieving British Isles Lupus Assessment Group Based Combined Lupus Assessment (BICLA) Response | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Placebo | Systemic Lupus Erythematosus | 1,014 | 2023-07-25 | Mar 2027 | ≤ 223 d | 2026-04-28 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132NCT06875960Number of participants treated with BMS-986165 | Phase 4 | Recruiting | Drug: BMS-986165 | Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) | 35 | 2026-02-24 | 2026-12-01 | in 103 d | 2026-03-30 |
| RNAC | Cartesian Therapeutics | $278M | Descartes-08 for Patients With Systemic Lupus ErythematosusNCT06038474Assess safety and tolerability of Descartes-08 in patients with systemic lupus erythematosus (SLE) | Phase 2 | Active, not recruiting | Drug: Descartes-08 | Systemic Lupus Erythematosus (SLE) | 6 | 2024-02-12 | 2026-12-01 | in 103 d | 2026-03-27 |
| CLYM | Climb Bio, Inc. | $999M | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)NCT07011043Incidence of Treatment-Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: Budoprutug | Systemic Lupus Erythematosus | 30 | 2025-07-10 | Apr 2027 | ≤ 253 d | 2026-03-27 |
| BMY | Bristol-Myers Squibb | $134.9B | Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusNCT03920267results2026-03-20Number of Participants With Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse Events | Phase 2 | Completed | Drug: BMS-986165 | Systemic Lupus Erythematosus | 261 | 2019-03-26 | 2025-03-21actual | — | 2026-03-20 |
| AZN | AstraZeneca | — | Saphnelo Use in Females of Child-bearing PotentialNCT07431775observationalIncidence of anifrolumab use | — | Not yet recruiting | Drug: Anifrolumab | Systemic Lupus Erythematosus | 26,000,000 | 2026-10-01 | 2032-03-31 | in 2,050 d | 2026-02-25 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLENCT05001737results2026-02-19Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab | Phase 3 | Completed | Drug: Emapalumab | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS | 33 | 2021-12-15 | 2024-06-30actual | — | 2026-02-19 |
| BIIB | Biogen | $31.4B | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04895241Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52 | Phase 3 | Active, not recruiting | Drug: Litifilimab, Placebo | Lupus Erythematosus, Systemic | 548 | 2021-05-25 | 2026-09-30 | in 41 d | 2026-02-10 |
| BIIB | Biogen | $31.4B | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04961567Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52 | Phase 3 | Active, not recruiting | Drug: Litifilimab, Placebo | Lupus Erythematosus, Systemic | 562 | 2021-07-16 | 2026-09-27 | in 38 d | 2026-01-29 |
| VOR | Vor Biopharma | $1.4B | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)NCT05306574SLE Responder Index (SRI-4) | Phase 3 | Terminatedsponsor's stated reason: Business decision | Biological: Telitacicept, Placebo | Systemic Lupus Erythematosus | 91 | 2022-06-20 | 2025-01-06actual | — | 2026-01-09 |
| VOR | Vor Biopharma | $1.4B | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)NCT06456567SLE Responder Index (SRI-4) | Phase 3 | Withdrawnsponsor's stated reason: Sponsor business decision | Biological: Telitacicept · Drug: Placebo | Systemic Lupus Erythematosus | 0 | Sep 2024 | 2025-01-02actual | — | 2026-01-09 |
| IPSC | Century Therapeutics, Inc. | $353M | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesNCT06255028Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs | Phase 1 | Active, not recruiting | Biological: CNTY-101, IL-2 · Drug: Lymphodepleting Chemotherapy | Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis | 6 | 2025-02-06 | Aug 2028 | ≤ 742 d | 2026-01-08 |
| AAPG | Ascentage Pharma Group Inc. | — | A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.NCT06182969Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. | Phase 1/2 | Recruiting | Drug: APG-2575 · Other: Placebo | SLE | 40 | 2024-08-09 | Apr 2026 | — | 2025-12-16 |
| AZN | AstraZeneca | — | This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLENCT06698900observationalUnderstand the difficulties faced by patients with SLE and identify gaps in diagnosis and treatment | — | Completed | — | Systemic Lupus Erythematosus | 1,000 | 2024-11-29 | 2024-12-20actual | — | 2025-12-16 |
| ARTV | Artiva Biotherapeutics, Inc. | $571M | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusNCT06265220Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events | Phase 1 | Active, not recruiting | Drug: AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab | Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE | 51 | 2024-04-03 | Aug 2027 | ≤ 376 d | 2025-12-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)NCT05617677Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] response | Phase 3 | Active, not recruiting | Drug: Deucravacitinib · Other: Placebo | Systemic Lupus Erythematosus | 516 | 2023-01-12 | 2026-10-19 | in 60 d | 2025-12-03 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusNCT05620407Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] response | Phase 3 | Active, not recruiting | Drug: Deucravacitinib · Other: Placebo | Systemic Lupus Erythematosus | 513 | 2023-01-12 | 2026-10-19 | in 60 d | 2025-12-02 |
| SANA | Sana Biotechnology | $1.1B | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)NCT06294236Evaluate safety and tolerability of SC291 | Phase 1 | Active, not recruiting | Biological: SC291 | Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis | 7 | 2024-04-29 | Dec 2027 | ≤ 498 d | 2025-11-25 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus ErythematosusNCT05411016Number of participants with adverse events (AEs) | Phase 1 | Active, not recruiting | Drug: Placebo, KK4277 | Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | 157 | 2022-08-03 | 2024-12-10actual | — | 2025-09-19 |
| CRBU | Caribou Biosciences, Inc. | $167M | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)NCT06752876Incidence of critical safety events (CSEs) ≤ 28days after CB-010 infusion | Phase 1 | Withdrawnsponsor's stated reason: Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs | Drug: CB-010 | Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Nephritis | 0 | Dec 2027 | Apr 2029 | ≤ 984 d | 2025-09-19 |
| AZN | AstraZeneca | — | Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in EgyptNCT07144514observationalDescription of the lupus-affected population | — | Not yet recruiting | — | Systemic Lupus Erythematosus | 276 | 2025-08-31 | 2025-12-31 | — | 2025-08-27 |
| AZN | AstraZeneca | — | Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.NCT06046534observationalDisease activity assessed by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) or any of its components at 6 months from the date of first anifrolumab infusion | — | Completed | Other: None (Observational study) | Systemic Lupus Erythematosus | 46 | 2023-10-27 | 2024-06-10actual | — | 2025-05-13 |
| ATRA | Atara Biotherapeutics | $88M | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus ErythematosusNCT06429800Number of Participants With treatment-emergent adverse events, including adverse events of special interest | Phase 1 | Withdrawnsponsor's stated reason: Financial | Drug: ATA3219 | Lupus Nephritis, Systemic Lupus Erythematosus | 0 | 2025-04-16 | 2025-04-16actual | — | 2025-04-24 |
| AZN | AstraZeneca | — | The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)NCT06056778observationalThe frequency of confirmed SLE in women with certain clinical manifestations and reproductive issues (early or late miscarriages, unknown infertility). | — | Completed | — | Systemic Lupus Erythematosus | 628 | 2023-09-28 | 2024-06-17actual | — | 2025-02-28 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)NCT06153095Phase I: Incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), and other treatment-emergent adverse events (TEAEs). | Phase 1/2 | Withdrawnsponsor's stated reason: Sponsor decision | Biological: IMPT-514, IMPT-514, IMPT-514 | Systemic Lupus Erythematosus, Lupus Nephritis | 0 | 2024-02-15 | 2025-01-09actual | — | 2025-02-10 |
| LLY | Eli Lilly and Company | $1.15T | A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus ErythematosusNCT05123586results2025-01-20Percentage of Participants With Arthritis and/or Rash at Baseline Who Achieve Remission of Arthritis and/or Rash | Phase 2 | Terminatedsponsor's stated reason: Study terminated due to lack of efficacy | Drug: LY3361237, Placebo | Systemic Lupus Erythematosus | 85 | 2022-03-07 | 2023-12-29actual | — | 2025-01-20 |
| ABBV | AbbVie | $457.5B | A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease StateNCT04451772results2025-01-14Number of Participants With Treatment-Emergent Adverse Events | Phase 2 | Completed | Drug: Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib | Systemic Lupus Erythematosus (SLE) | 185 | 2020-07-27 | 2024-01-03actual | — | 2025-01-14 |
| AMGN | Amgen | $229.9B | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and DermatomyositisNCT03817424Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Phase 1 | Completed | Drug: VIB7734, Placebo | Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis | 31 | 2018-12-13 | 2020-07-20actual | — | 2024-12-13 |
| AMGN | Amgen | $229.9B | Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)NCT04058028results2024-09-24Number of Participants With a SLE Responder Index (SRI-4) Response at Week 52 | Phase 2 | Completed | Drug: Rozibafusp Alfa, Placebo for Rozibafusp Alfa | Systemic Lupus Erythematosus (SLE) | 244 | 2020-02-19 | 2023-07-25actual | — | 2024-09-24 |
| AMGN | Amgen | $229.9B | Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension StudyNCT05430854results2024-09-19Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: Daxdilimab | Systemic Lupus Erythematosus | 155 | 2022-06-01 | 2023-10-31actual | — | 2024-09-19 |
| PFE | Pfizer | $155.3B | A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)NCT03845517results2024-09-05Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52 | Phase 2 | Completed | Drug: Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg | Systemic Lupus Erythematosus | 350 | 2019-04-18 | 2023-10-05actual | — | 2024-09-05 |
| AMGN | Amgen | $229.9B | Study of VIB7734 for the Treatment of Moderate to Severely Active SLENCT04925934results2024-07-23Number of Participants Achieving a BILAG-2004 Index-based Combined Lupus Assessment (BICLA) Response and an OGC Dose ≤ 7.5 mg/Day and ≤ Baseline Dose of Prednisone or Equivalent at Week 48 | Phase 2 | Completed | Drug: VIB7734 · Other: Placebo | Lupus Erythematosus, Systemic | 214 | 2021-05-28 | 2023-05-16actual | — | 2024-07-23 |
| AMGN | Amgen | $229.9B | Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus ErythematosusNCT04680637results2024-06-28Number of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response at Week 52 | Phase 2 | Terminatedsponsor's stated reason: The trial was terminated prematurely as it met pre-defined criteria for futility at IA3. | Drug: Efavaleukin Alfa, Placebo · Other: Standard of Care | Active Systemic Lupus Erythematosus | 168 | 2021-05-06 | 2023-05-22actual | — | 2024-06-28 |
| OGN | Organon and Co | $3.6B | Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)NCT00739050results2010-12-16Change From Baseline in Endothelial Thickness After 12 Weeks of Treatment. | Phase 4 | Terminated | Drug: simvastatin, Comparator: Placebo | Systemic Lupus Erythematosus | 4 | 2007-09-19 | 2008-02-01actual | — | 2024-05-23 |
| AMGN | Amgen | $229.9B | Single Ascending Dose Study of AMG 570 in Healthy SubjectsNCT02618967results2021-10-15Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Completed | Biological: AMG 570, AMG 570 Matching Placebo | Systemic Lupus Erythematosus | 56 | 2016-03-28 | 2018-09-06actual | — | 2024-05-14 |
| NKTR | Nektar Therapeutics | $2.5B | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)NCT04433585results2024-04-23Percentage of Participants Who Achieved a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score at Week 24 | Phase 2 | Completed | Drug: LY3471851, Placebo | Systemic Lupus Erythematosus | 291 | 2020-08-19 | 2023-01-10actual | — | 2024-04-23 |
| AZN | AstraZeneca | — | Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)NCT03189875observationalDisease activity | — | Completed | Other: Standard of Care | Systemic Lupus Erythematosus | 830 | 2017-06-28 | 2022-11-18actual | — | 2024-02-28 |
| BMY | Bristol-Myers Squibb | $134.9B | Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisNCT04186871results2024-01-16The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE | Phase 2 | Completed | Drug: branebrutinib, abatacept, branebrutinib placebo | Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome | 119 | 2020-01-07 | 2022-12-05actual | — | 2024-01-16 |
| NKTR | Nektar Therapeutics | $2.5B | A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)NCT03556007Safety and Tolerability of LY3471851 - Number of Participants Experiencing Adverse Events | Phase 1 | Completed | Drug: LY3471851, Placebo | Systemic Lupus Erythematosus | 48 | 2018-04-18 | 2019-08-29actual | — | 2023-11-18 |
| BIIB | Biogen | $31.4B | Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)NCT02847598results2023-05-15Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 | Phase 2 | Completed | Drug: BIIB059 (litifilimab), Placebo | Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus | 264 | 2016-10-20 | 2019-08-28actual | — | 2023-11-07 |
| PFE | Pfizer | $155.3B | Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid ArthritisNCT03334851results2023-10-30Number of Participants With Dose-Limiting Toxicity (DLT) | Phase 1 | Completed | Drug: PF-06835375, Placebo | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 74 | 2017-11-17 | 2022-02-15actual | — | 2023-10-30 |
| SNN | Smith & Nephew, Inc. | — | Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint ProsthesisNCT02408471results2023-10-10Number of Participants With Revisions | Not applicable | Terminatedsponsor's stated reason: Business Priorities | Device: Ascension® MCP Finger Implant | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Post-traumatic Arthritis | 97 | Jun 2002 | Jan 2015actual | — | 2023-10-10 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus ParticipantsNCT05278663Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1/2 | Completed | Drug: E6742 · Other: Placebo | Lupus Erythematosus, Systemic | 26 | 2022-04-14 | 2023-09-04actual | — | 2023-09-29 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy ParticipantsNCT05984251Number of Participants Experiencing Adverse Events (AEs) | Phase 1 | Completed | Drug: CCX168, Placebo | Vasculitis, Systemic Lupus Erythematosus (SLE) | 48 | 2009-12-21 | 2010-09-19actual | — | 2023-08-09 |
| ABBV | AbbVie | $457.5B | A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)NCT03978520results2023-07-21Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24 | Phase 2 | Completed | Drug: Elsubrutinib, Placebo for elsubrutinib, Upadacitinib, Placebo for upadacitinib | Systemic Lupus Erythematosus (SLE) | 341 | 2019-07-25 | 2022-01-19actual | — | 2023-07-21 |
| AMGN | Amgen | $229.9B | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus ErythematosusNCT03451422results2023-07-19Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Phase 1 | Completed | Drug: Efavaleukin Alfa, Placebo | Systemic Lupus Erythematosus | 35 | 2018-04-10 | 2021-10-12actual | — | 2023-07-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)NCT03843125results2023-05-16Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Terminatedsponsor's stated reason: Study terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data | Drug: Baricitinib, Placebo | Systemic Lupus Erythematosus | 1,147 | 2019-09-09 | 2022-04-01actual | — | 2023-05-16 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of a Single Ascending Dose Study of DS-7011a in Healthy SubjectsNCT05203692Number of Participants with Treatment-emergent Adverse Events Following Administration with DS-7011a in Healthy Participants | Phase 1 | Completed | Drug: DS-7011a, Placebo | Systemic Lupus Erythematosus | 80 | 2022-02-02 | 2023-01-25actual | — | 2023-04-11 |
| BIIB | Biogen | $31.4B | Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus ErythematosusNCT02106897Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Completed | Drug: BIIB059 (litifilimab), Placebo | Systemic Lupus Erythematosus, Healthy Volunteers | 109 | 2014-04-30 | 2016-05-24actual | — | 2023-01-31 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusNCT03616912results2023-01-30Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib) | Phase 3 | Terminatedsponsor's stated reason: Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients. | Drug: Baricitinib, Placebo | Systemic Lupus Erythematosus | 830 | 2018-08-02 | 2021-11-01actual | — | 2023-01-30 |
| AZN | AstraZeneca | — | Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus ErythematosusNCT02794285results2023-01-13Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs) | Phase 3 | Completed | Biological: Anifrolumab · Drug: Placebo | Active Systemic Lupus Erythematosus | 559 | 2016-06-30 | 2021-12-21actual | — | 2023-01-13 |
| AZN | AstraZeneca | — | Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusNCT02446912results2019-12-05Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules) | Phase 3 | Completed | Biological: Anifrolumab · Drug: Placebo | Active Systemic Lupus Erythematosus | 460 | 2015-06-09 | 2018-07-17actual | — | 2023-01-12 |
| AZN | AstraZeneca | — | A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin ManifestationsNCT02962960results2019-12-18Maximum Concentration of Anifrolumab in Serum After First Dose | Phase 2 | Completed | Drug: Anifrolumab, Placebo | Systemic Lupus Erythematosus | 36 | 2017-02-14 | 2018-01-22actual | — | 2023-01-12 |
| AZN | AstraZeneca | — | Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusNCT02446899results2020-03-18Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 | Phase 3 | Completed | Biological: Anifrolumab · Drug: Placebo | Active Systemic Lupus Erythematosus | 373 | 2015-07-09 | 2018-09-27actual | — | 2023-01-10 |
| BMY | Bristol-Myers Squibb | $134.9B | An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusNCT03252587results2022-09-10Number of Participants Who Meet Response Criteria for Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] at Week 32 | Phase 2 | Completed | Drug: BMS-986165 · Other: Placebo | Systemic Lupus Erythematosus | 363 | 2017-09-21 | 2021-06-29actual | — | 2022-12-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)NCT03616964results2022-11-23Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib) | Phase 3 | Completed | Drug: Baricitinib, Placebo | Systemic Lupus Erythematosus | 778 | 2018-08-02 | 2021-09-24actual | — | 2022-11-23 |
| AZN | AstraZeneca | — | Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)NCT05001698Time to maximum observed plasma concentration (Tmax) of anifrolumab. | Phase 1 | Completed | Biological: Anifrolumab | Systemic Lupus Erythematosus | 15 | 2021-07-27 | 2022-06-02actual | — | 2022-08-18 |
| GILD | Gilead Sciences | $177.9B | Phase Ib Study of SC Milatuzumab in SLENCT01845740Safety and Tolerability | Phase 1 | Completed | Drug: milatuzumab, Placebo | Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis | 22 | Jan 2007 | Jun 2009actual | — | 2021-08-19 |
| AZN | AstraZeneca | — | Anifrolumab Early Access ProgramNCT04750057expanded access | — | No longer available | Drug: Anifrolumab | Systemic Lupus Erythematosus | — | — | — | — | 2021-05-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3361237 in Participants With Systemic Lupus ErythematosusNCT03933943Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug | Phase 1 | Completed | Drug: LY3361237, Placebo | Lupus Erythematosus, Systemic | 28 | 2019-05-21 | 2021-02-15actual | — | 2021-03-04 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Systemic Lupus Erythematosus is matched — 6 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Systemic Lupus Erythematosus
- Lupus Erythematosus, Systemic
- Systemic Lupus Erythematosus (SLE)
- Active Systemic Lupus Erythematosus
- SLE
- SLE (Systemic Lupus)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Systemic Lupus Erythematosus” (a text search, wider than this page)